Answers are grounded in this paper and cite their sources.
This Viewpoint discusses the legal entanglements that can block generic drug competition on patents flagged for delisting.
No takes yet. Share an insight, caveat, or question.
Gabriele et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: